1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow GCS-100: new trials by email Literature Review of GCS-100 trials Research Report on GCS-100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of GCS-100 to Treat Chronic Kidney Disease GCS-100 - Chronic Kidney Disease | Phase 1 | Completed | La Jolla Pharmaceutical Company | 29 | 2013-01-01 | 2013-06-20 |
| GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma GCS-100, Etoposide; Dexamethasone - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | La Jolla Pharmaceutical Company | 2008-07-01 | 2013-06-25 | |
| Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma GCS-100, Bortezomib/Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | La Jolla Pharmaceutical Company | 9 | 2008-05-01 | 2013-06-25 |
Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Recurrence (1) · Renal Insufficiency, Chronic (1)
La Jolla Pharmaceutical Company (3)
United States (3)
Bhupinder Singh, MD (1) · Geoffrey Block, MD (1) · George Fadda, MD (1) · Lauren Pinter-Brown, MD (1) · Pablo Pergola, MD (1) · Robert Schlossman, MD (1)